Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug symbols : GILD save search
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.39%
H: 0.82%
C: -0.74%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.22%
H: 0.43%
C: -0.39%
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -63.33%
H: 263.64%
C: 127.27%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL | $4.8 -0.83% -0.83% 1.2M
|
Health Technology
|
| O: -0.91%
H: 11.52%
C: 4.94%
drug report t-cell global therapy market
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.68 -1.92% -1.96% 730K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.76 -4.03% 0.0% 280K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO M | $3.76 -1.05% -1.06% 770K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Lyndra Therapeutics’ LYNX™ Drug Delivery Platform Wins 2022 Fierce Life Sciences Innovation Award for Drug Delivery Technology
Published: 2022-11-15 (Crawled : 21:00) - biospace.com/
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.34%
H: 0.61%
C: -0.16%
award sciences drug life technology innovation platform
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Published: 2022-11-02 (Crawled : 12:00) - biospace.com/
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -1.46%
H: 2.33%
C: -0.38%
vemlidy treatment hepatitis drug virus food infection chronic hepatitis b
Global Pulmonary Arterial Hypertension Drug Market to Surpass US$ 11,220.2 Million by 2030 - Coherent Market Insights
Published: 2022-09-13 (Crawled : 19:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -4.98%
H: 7.63%
C: 2.67%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.55%
H: 0.42%
C: -0.72%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.41%
C: -0.76%
UTHR | $237.16 0.79% 0.78% 480K
|
Health Technology
|
| O: 0.63%
H: 0.81%
C: 0.57%
MNKD | $4.08 -0.49% -0.49% 1.3M
|
Health Technology
|
| O: 0.0%
H: 5.91%
C: 3.67%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -1.06%
H: 1.63%
C: 1.2%
drug global hypertension market
Disease-Modifying Antirheumatic Drug (DMARD) Market to Surpass US$ 27,167.8 Million by 2030 - Coherent Market Insights
Published: 2022-09-06 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: 0.0%
UCBJY | $64.07 -4.38% 72K
|
Manufacturing
|
| O: 0.73%
H: 2.28%
C: 1.72%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.65%
H: 0.93%
C: 0.71%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.03%
H: 1.18%
C: 0.13%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.03%
H: 1.08%
C: 0.84%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.44%
H: 2.03%
C: 1.76%
CPIX | $1.57 6.02% 1.4K
|
Health Technology
|
| O: -4.52%
H: 7.12%
C: 5.69%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.24%
H: 1.04%
C: 0.82%
drug market
A $41.8 Billion Global Opportunity for Small Molecule Drug Discovery by 2026 - New Research from StrategyR
Published: 2022-07-04 (Crawled : 11:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
| Email alert
Add to watchlist
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
| Email alert
Add to watchlist
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $140.15 -4.19% 560
|
Health Technology
| Email alert
Add to watchlist
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
| Email alert
Add to watchlist
drug research
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Published: 2022-06-24 (Crawled : 13:00) - biospace.com/
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 1.52%
H: 0.0%
C: 0.0%
chmp hiv positive drug
Antiviral Drugs Market Size To Reach USD 50.02 BN In 2030 Due to Development Of New, Improved, And More Advanced Formulations, Such As Repurposed Drugs And Drug Combination Therapies, Says Reports and Data
Published: 2022-04-13 (Crawled : 15:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.76%
H: 0.35%
C: 0.35%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -0.83%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.12%
H: 0.44%
C: 0.17%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.24%
H: 0.45%
C: 0.39%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.02%
H: 0.8%
C: 0.71%
drug antiviral repurposed market
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-03-30 (Crawled : 01:00) - biospace.com/
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.18%
H: 0.53%
C: -1.26%
drug application cancer breast cancer
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-03-31 (Crawled : 01:00) - prnewswire.com
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.52%
H: 0.08%
C: -0.87%
drug application cancer breast cancer
Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments
Published: 2022-03-15 (Crawled : 16:00) - prnewswire.com
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.47%
H: 0.62%
C: -0.18%
covid-19 viral drug treatment drug covid therapy antiviral
Hematological Malignancies Drugs Market worth $ 42.78 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-03-08 (Crawled : 11:00) - prnewswire.com
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -0.14%
H: 5.36%
C: 5.36%
TAK | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -2.75%
H: 0.28%
C: -1.04%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.38%
H: 1.81%
C: 0.28%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -1.55%
H: 0.71%
C: -0.28%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 1.4%
H: 0.7%
C: -1.15%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -0.3%
H: 3.38%
C: 0.32%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
ema drug report
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-02-07 (Crawled : 01:00) - prnewswire.com
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -1.42%
H: 0.0%
C: 0.0%
trodelvy drug approval cancer negative breast cancer
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-01-04 (Crawled : 01:00) - prnewswire.com
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
new drug fda application drug cancer negative breast cancer
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published: 2021-12-14 (Crawled : 01:00) - biospace.com/
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
new drug application drug cancer negative breast cancer
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published: 2021-12-15 (Crawled : 01:00) - prnewswire.com
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.99%
H: 1.23%
C: 0.94%
new drug application drug cancer negative breast cancer
Global HIV-1 Market and Epidemiology Overview 2018-2030 with Insights Into Marketed & Emerging Drugs from Merck Sharp & Dohme, Gilead Sciences, and ViiV Healthcare
Published: 2021-12-08 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.14%
H: 0.34%
C: 0.34%
THTX | $1.32 -12.78% 10K
|
Health Technology
|
| O: -2.48%
H: 4.46%
C: 3.5%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.54%
H: 0.0%
C: 0.0%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.72%
H: 0.82%
C: -0.29%
thc drug hiv
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC)
Published: 2021-11-29 (Crawled : 13:00) - biospace.com/
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | News | $4.16 -2.8% -2.88% 690K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
phase 2 trilaciclib antibody drug trial therapeutics
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | News | $4.16 -2.8% -2.88% 690K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
trodelvy phase 2 trilaciclib antibody drug trial therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.